DEF 14A: ProMIS Neurosciences Seeks Shareholder Approval for Warrant Issuance to Comply with Nasdaq Rules

ProMIS Neurosciences is holding a special meeting to seek shareholder approval for the potential issuance of common shares underlying warrants from a recent private placement, as required by Nasdaq listing rules.

Summary

• ProMIS Neurosciences Inc. is convening a Special Meeting of Shareholders on October 23, 2024, to address two key proposals.
• The primary purpose is to gain shareholder approval for the potential issuance of common shares related to Tranche A and Tranche B warrants, which were part of a private placement that closed on July 31, 2024, raising approximately $30.3 million.
• This approval is necessary to comply with Nasdaq Listing Rule 5635(d).
• If the primary proposal fails to pass, a second proposal seeks approval to adjourn the Special Meeting to a later date, no later than November 22, 2024, to solicit additional proxies.
• Holders of 9,757,669 common shares issued under the Unit Purchase Agreement dated July 26, 2024, will not be entitled to vote such shares.
• As a result, a total of 20,127,783 Common Shares are entitled to vote on Proposal 1 and Proposal 2.
• The board of directors recommends voting in favor of both proposals.

Sentiment

Score: 7

Explanation: The document is primarily procedural, outlining the need for shareholder approval. The sentiment is neutral to slightly positive due to the successful completion of the private placement, but there are risks associated with not obtaining shareholder approval.

Positives

• Successful completion of a private placement, raising approximately $30.3 million.
• The board of directors is actively seeking shareholder approval to comply with Nasdaq requirements.
• The company has a plan to adjourn the meeting to solicit additional proxies if the initial vote is insufficient.

Negatives

• Failure to secure shareholder approval for the warrant issuance could prevent the exercise of Tranche A and Tranche B warrants.
• The company may incur additional costs and expenses associated with repeated attempts to obtain shareholder approval.
• Existing shareholders may experience dilution in their ownership interests if the warrants are exercised.

Risks

• Failure to obtain shareholder approval could prevent the company from receiving up to approximately $57.1 million in gross proceeds from the exercise of Tranche A and Tranche B warrants.
• Inability to exercise the warrants could adversely impact the company's ability to fund its operations, including the planned Phase 1(b) study of PMN310.
• Repeatedly seeking shareholder approval could materially and adversely impact the company's ability to fund its operations and advance clinical development of PMN310.
• Existing shareholders will suffer dilution in their ownership interests if the Tranche A Warrants and the Tranche B Warrants are exercised.

Future Outlook

The company plans to continue seeking shareholder approval for the warrant issuance every 90 days until approval is obtained or the warrants are no longer outstanding.

Management Comments

• The content and sending of the proxy statement has been authorized by order of the Board of Directors, Neil K. Warma, Interim Chief Executive Officer.

Industry Context

This announcement reflects a common practice for companies listed on Nasdaq to ensure compliance with listing rules related to the issuance of shares and warrants, particularly when involving significant percentages of outstanding shares.

Comparison to Industry Standards

• Seeking shareholder approval for warrant exercises is a standard practice for Nasdaq-listed companies when the potential issuance exceeds 20% of outstanding shares, similar to requirements faced by companies like Cassava Sciences and Anavex Life Sciences when issuing shares or convertible securities.
• The at-the-market pricing of the private placement aligns with industry norms for raising capital, as seen with companies like Amylyx Pharmaceuticals, which also utilized similar financing strategies to fund clinical trials.
• The virtual format of the special meeting is increasingly common, mirroring practices adopted by companies like Biogen and Eli Lilly to enhance shareholder accessibility and participation.

Stakeholder Impact

• Shareholders will be impacted by the outcome of the vote, potentially experiencing dilution if the warrants are exercised.
• The company's ability to fund operations and clinical trials could be affected by the success or failure of the warrant issuance.
• The company's reputation and compliance with Nasdaq listing rules are at stake.

Next Steps

• Shareholders will vote on the proposals at the Special Meeting on October 23, 2024.
• The company will announce preliminary voting results at the Special Meeting and report final results in a Form 8-K.
• If Proposal 1 fails, the company will adjourn the meeting and solicit additional proxies, with a deadline of November 22, 2024.
• The company will continue to seek shareholder approval every 90 days until approval is obtained or the warrants are no longer outstanding.

Key Dates

Keywords

shareholder approval, warrant issuance, private placement, Nasdaq Listing Rule 5635(d), ProMIS Neurosciences, Tranche A Warrants, Tranche B Warrants, PMN310, proxy statement, special meeting